Would you consider a PARP inhibitor in the treatment of a PARP inhibitor naïve platinum resistant recurrent ovarian cancer with LOH/HRD?

These are challenging scenarios and with increasing PARP use in the upfront setting, especially (likely) in the LOH/HRD patients I suspect this clinical scenario may become less frequent in the future. For now, it's appealing to suggest that LOH/HRD scores as a biomarker can be examined in a vacuum but platinum response is likely a critically important consideration in PARP response.

While certainly platinum resistant disease provides challenges in treatment and in clinical practice, I certainly would consider it … the data for efficacy in platinum resistant disease is less supportive.

I'll quote Dr. Swisher's paper from Nature Communications (2021) with their finding regarding HRD scar persistence and rucaparib use in Ariel.

"Genomic scars a...